Stayble Therapeutics publishes interim report for the third quarter of 2023
Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes its quarterly report for the third quarter of 2023. The report is available as an attached document and on the Company's website, www.staybletherapeutics.com/en/investors/financial-reports/. Below is a summary of the report.Summary Highlights during the third quarter (July – September 2023) · In July, Stayble announced that about 90% of the patients in the ongoing Phase IIb study for treating degenerative disc diseases have completed their twelve-month follow-up. · In August, the first patient was included